Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
根據早前報道，Alnylam的Vutrisiran數據突出顯示對關鍵心臟生物標誌物的早期影響，Alnylam將首選用於ATTR澱粉樣蛋白沉積症的一線治療。
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An open access recording of Alnylam presentations will be available on the HFSA website following the session.
納斯達克(ALNY)領先的RNAi治療公司Alnylam Pharmaceuticals, Inc.宣佈，HELios-b Phase 3研究中vutrisiran的兩組新數據集已在2024年心力衰竭學會(HFSA)年度科學會議Late Breaking Clinical Research Session 1上報告。該會議是以虛擬形式舉行的。Alnylam的演示資料將在會後在HFSA網站上提供免費播放。
Progression in ATTR-CM is associated with cardiac wall thickening, deterioration in systolic and diastolic function and increases...
ATTR-Cm的進展與心臟壁增厚、收...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。